デフォルト表紙
市場調査レポート
商品コード
1405987

細胞・遺伝子治療CDMOの市場規模、シェア、動向分析レポート:フェーズ別、製品タイプ別、適応症別、地域別、セグメント別予測、2024年~2030年

Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product Type, By Indication, By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 195 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
細胞・遺伝子治療CDMOの市場規模、シェア、動向分析レポート:フェーズ別、製品タイプ別、適応症別、地域別、セグメント別予測、2024年~2030年
出版日: 2023年12月14日
発行: Grand View Research
ページ情報: 英文 195 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞・遺伝子治療CDMO市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の細胞・遺伝子治療CDMO市場規模は2030年までに274億5,000万米ドルに達すると予測され、2024年から2030年までのCAGRは27.9%で成長すると予測されています。

細胞・遺伝子治療における研究開発活動の開発、希少疾患への対応への注目の高まり、革新的な製品のパイプラインの拡大、この分野におけるアウトソーシングサービスに対するニーズの高まり、開発プロセスにおける継続的な技術進歩などが、市場需要の高まりに寄与しています。

さらに、新規の細胞・遺伝子治療薬の開発に向けた民間・公的セクターからの投資や資金提供の増加も、市場の成長を支える重要な要因となっています。細胞・遺伝子治療市場への投資と資金提供の注目すべき例を以下にいくつか挙げる:

  • 2021年8月、遺伝子編集診断に特化した企業であるSeQure Dx社は、遺伝子治療薬を開発するために1,750万米ドルのシリーズA資金調達ラウンドを発表しました。この資金調達はMass General Brigham VenturesとRiverVest Venture Partnersが主導し、Casdin Capital、Digitalis Ventures、KdT Ventures、Alexandria Venture Investments、Bold Capital Partnersが参加しました。
  • 2021年8月、眼科疾患に対する非ウィルス性遺伝子治療に焦点を当てた臨床段階のバイオテクノロジー企業であるEyevensysは、シリーズBプラス資金調達ラウンドで1,200万米ドルを確保しました。

COVID-19パンデミックの初期段階は市場に悪影響を与えました。臨床試験活動全体の停滞は、主に参加者とスタッフの安全性への懸念から、遅延や一時的な中断につながったことが大きな要因でした。サプライチェーン管理、特に輸送とロジスティクスの混乱は課題をもたらし、パンデミックをめぐる不確実性は需要予測と実現可能性計画の全般的な欠如を生み出しました。しかし、新たな規範への適応、サプライチェーンの回復力の強化、パンデミックによってもたらされた課題を乗り切るための安全対策の実施などを組み合わせることによって、市場は回復しました。さらに、主要企業が採用した合併・買収戦略は、2021年までにパンデミックの悪影響を軽減するのに役立っています。

細胞・遺伝子治療CDMO市場レポートハイライト

  • 前臨床部門は2023年に66.2%の最大シェアを占める。細胞・遺伝子治療薬のパイプラインが増加していることが、このセグメントの成長を支える主な要因の一つです。
  • 製品タイプ別では、細胞治療分野が2023年に41.6%の最大シェアを占めました。細胞治療サービスは、再生医療と個別化医療の進展に不可欠です。
  • 希少疾患のCAGRは、分析期間を通じて28.4%と最も高くなると予測されています。いくつかの希少疾患の有病率の増加が細胞・遺伝子治療の研究開発活動の急増につながり、この分野の成長を支えています。
  • アジア太平洋地域は予測期間中に29.0%のCAGRを記録すると予測されています。同地域の大幅な成長は、主にアジアのいくつかの経済圏で人件費と運営コストが低いため、細胞・遺伝子製品のコスト効率のよい製造が可能であることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 細胞・遺伝子治療CDMO市場の変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 細胞・遺伝子治療のCDMO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 細胞・遺伝子治療CDMO市場:フェーズの推定・動向分析

  • 細胞・遺伝子治療CDMO市場、フェーズ別:セグメントダッシュボード
  • 細胞・遺伝子治療CDMO市場、フェーズ別:変動分析
    • 前臨床
    • 臨床

第5章 細胞・遺伝子治療CDMO市場:製品タイプの推定・動向分析

  • 細胞・遺伝子治療CDMO市場、製品タイプ別:セグメントダッシュボード
  • 細胞・遺伝子治療CDMO市場、製品タイプ別:変動分析
    • 遺伝子治療
    • 遺伝子組換え細胞治療
    • 細胞治療

第6章 細胞・遺伝子治療CDMO市場:適応症の推定・動向分析

  • 細胞・遺伝子治療のCDMO市場、適応症別:セグメントダッシュボード
  • 細胞・遺伝子治療のCDMO市場、適応症別:変動分析
    • 腫瘍
    • 感染症
    • 神経学的障害
    • 希少疾患
    • その他

第7章 細胞・遺伝子治療CDMO市場:地域の推定・動向分析

  • 地域の市場シェア分析、2023年および2030年
  • 地域の市場ダッシュボード
  • 世界の地域の市場スナップショット
  • 北米
    • 市場推計・予測、2018~2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2023年
  • 企業プロファイル
    • Lonza
    • Catalent, Inc
    • Cytiva
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • Novartis AG
    • WuXi AppTec
    • AGC Biologics
    • OmniaBio
    • Rentschler Biopharma SE
    • Charles River Laboratories
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 5 North America Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 6 North America Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 7 North America Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 8 North America Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 17 Canada Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Canada Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 19 Europe Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 21 Europe Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 22 Europe Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 23 Europe Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Europe Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 25 UK Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 26 UK Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 27 UK Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 28 UK Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 29 UK Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 30 Germany Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 32 Germany Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 33 Germany Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 34 Germany Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 France Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 36 France Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 37 France Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 38 France Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 France Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 40 Italy Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 41 Italy Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 42 Italy Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 43 Italy Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 44 Italy Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 45 Spain Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 46 Spain Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 47 Spain Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 48 Spain Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 49 Spain Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 50 Denmark Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 52 Denmark Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 53 Denmark Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 54 Denmark Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 55 Sweden Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 56 Sweden Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 57 Sweden Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 58 Sweden Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 59 Sweden Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 60 Norway Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 61 Norway Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 62 Norway Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 63 Norway Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 64 Norway Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 71 China Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 72 China Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 73 China Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 74 China Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 75 China Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 76 Japan Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 77 Japan Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 78 Japan Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 79 Japan Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 80 Japan Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 81 India Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 82 India Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 83 India Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 84 India Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 85 India Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 86 Australia Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 87 Australia Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 88 Australia Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 89 Australia Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Australia Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 91 South Korea Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 92 South Korea Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 93 South Korea Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 94 South Korea Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 95 South Korea Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 96 Thailand Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 97 Thailand Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 98 Thailand Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 99 Thailand Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 100 Thailand Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 101 Latin America Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 102 Latin America Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 103 Latin America Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 104 Latin America Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 105 Latin America Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 106 Latin America Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 107 Brazil Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 108 Brazil Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 109 Brazil Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 110 Brazil Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 111 Brazil Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 112 Mexico Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 113 Mexico Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 114 Mexico Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 115 Mexico Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 116 Mexico Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 117 Argentina Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 118 Argentina Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 119 Argentina Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 120 Argentina Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 121 Argentina Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 122 Middle East and Africa Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 123 Middle East and Africa Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 124 Middle East and Africa Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 125 Middle East and Africa Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 126 Middle East and Africa Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 127 Middle East and Africa Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 128 South Africa Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 129 South Africa Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 130 South Africa Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 131 South Africa Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 132 South Africa Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 137 Saudi Arabia Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 138 UAE Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 139 UAE Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 140 UAE Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 141 UAE Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 142 UAE Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 143 Kuwait Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 144 Kuwait Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 145 Kuwait Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 146 Kuwait Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 147 Kuwait Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary Interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Cell and Gene Therapy CDMO market segmentation
  • Fig. 18 Parent market outlook (2023)
  • Fig. 19 Related/ancillary market outlook (2023)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Market restraint relevance analysis (Current & future impact)
  • Fig. 22 Porter's Five Forces analysis
  • Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 24 Cell and Gene Therapy CDMO Market Phase Outlook: Segment dashboard
  • Fig. 25 Cell and Gene Therapy CDMO: Phase movement analysis
  • Fig. 26 Pre-clinical market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 28 Cell and Gene Therapy CDMO Market Product Type Outlook: Segment dashboard
  • Fig. 29 Cell and Gene Therapy CDMO: Product Type type movement analysis
  • Fig. 30 Gene Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 Ex-vivo market, 2018 - 2030 (USD Million)
  • Fig. 32 In-vivo market, 2018 - 2030 (USD Million)
  • Fig. 33 Gene-Modified Cell Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 CAR T-cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 35 CAR-NK cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 36 TCR-T cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other market, 2018 - 2030 (USD Million)
  • Fig. 38 Cell Therapy market, 2018 - 2030 (USD Million)
  • Fig. 39 Cell and Gene Therapy CDMO market Indication outlook: Segment dashboard
  • Fig. 40 Cell and Gene Therapy CDMO market: Indication movement analysis
  • Fig. 41 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 42 Infectious Diseases market, 2018 - 2030 (USD Million)
  • Fig. 43 Neurological Disorders market, 2018 - 2030 (USD Million)
  • Fig. 44 Rare Diseases market, 2018 - 2030 (USD Million)
  • Fig. 45 Others market, 2018 - 2030 (USD Million)
  • Fig. 46 Regional marketplace: Segment dashboard
  • Fig. 47 Regional outlook, 2023 & 2030
  • Fig. 48 North America market, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 50 Canada market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market, 2018 - 2030 (USD Million)
  • Fig. 53 UK market, 2018 - 2030 (USD Million)
  • Fig. 54 France market, 2018 - 2030 (USD Million)
  • Fig. 55 Italy market, 2018 - 2030 (USD Million)
  • Fig. 56 Spain market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark market, 2018 - 2030(USD Million)
  • Fig. 58 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 China market, 2018 - 2030 (USD Million)
  • Fig. 62 Japan market, 2018 - 2030 (USD Million)
  • Fig. 63 India market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 71 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-167-4

Cell And Gene Therapy CDMO Market Growth & Trends:

The global cell and gene therapy CDMO market size is expected to reach USD 27.45 billion by 2030 and is projected to grow at a CAGR of 27.9% from 2024 to 2030, according to a new report by Grand View Research, Inc.Growing research and development activities in cell and gene therapies, heightened focus on addressing rare diseases, the expanding pipeline of innovative products, a rising need for outsourced services in this field, and continuous technological advancements in the development processes are few of the factors collectively contribute to rising demand for the market.

Furthermore, increasing investments and funding from private and public sectors to develop novel cell and gene therapeutics is another significant factor supporting the market growth. A few of the notable examples of investments and funding in the cell and gene therapy market are mentioned below:

  • In August 2021 SeQure Dx, a company specializing in gene editing diagnostics, announced a series A funding round of USD 17.5 million to develop gene therapeutics. This funding was led by Mass General Brigham Ventures and RiverVest Venture Partners, along with Casdin Capital, Digitalis Ventures, KdT Ventures, Alexandria Venture Investments, and Bold Capital Partners
  • In August 2021, Eyevensys, a clinical-stage biotechnology company focusing on nonviral gene therapies for ophthalmic diseases, secured USD 12 million in a series B plus funding round

The initial phase of the COVID-19 pandemic adversely affected the market. The slowdown in overall clinical trial activity was a significant factor, primarily due to concerns about the safety of participants and staff, leading to delays and temporary suspensions. The disruption in supply chain management, particularly in transportation and logistics, posed challenges, and the uncertainty surrounding the pandemic created a general lack of demand forecast and feasibility planning. However, the market recovered through a combination of adapting to new norms, enhancing the resilience of supply chains, and implementing safety measures to navigate the challenges posed by the pandemic. Moreover, mergers and acquisition strategies adopted by the major companies have helped mitigate the negative impact of the pandemic by 2021.

Cell And Gene Therapy CDMO Market Report Highlights:

  • The pre-clinical segment accounted for the largest share of 66.2% in 2023. The increasing pipeline of cell and gene therapeutics is one of the major factors supporting the segment's growth
  • Based on the product type, the cell therapy segment accounted for the largest share of 41.6% in 2023. Cell therapy services are vital in advancing regenerative medicine & personalized medicine
  • Rare diseases are anticipated to witness the highest CAGR of 28.4% across the analysis period. The growing prevalence of several rare diseases has led to a surge in R&D activities in cell and gene therapies, thus supporting segmental growth
  • Asia Pacific is anticipated to witness the highest CAGR of 29.0% during the forecast time frame. The region's substantial growth is primarily attributed to the cost-effective manufacturing of cell and gene products due to lower labor and operational costs in several Asian economies

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Phase
    • 1.1.3. Product Type
    • 1.1.4. Indication
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cell and Gene Therapy CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing pipeline of cell and gene therapy products to boost the market growth
      • 3.2.1.2. Increasing investments and R&D funding for the development of cell and gene therapeutics
      • 3.2.1.3. Technological innovations across the cell & gene therapy development process
      • 3.2.1.4. Increasing mergers & acquisitions in the cell and gene therapy industry
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. High development costs of CGT products
  • 3.3. Cell and Gene Therapy CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

  • 4.1. Cell and Gene Therapy CDMO Market, By Phase: Segment Dashboard
  • 4.2. Cell and Gene Therapy CDMO Market, By Phase: Movement Analysis
  • 4.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 4.3.1. Pre-clinical
      • 4.3.1.1. Pre-clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Clinical
      • 4.3.2.1. Clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Cell and Gene Therapy CDMO Market: Product Type Estimates & Trend Analysis

  • 5.1. Cell and Gene Therapy CDMO Market, By Product Type: Segment Dashboard
  • 5.2. Cell and Gene Therapy CDMO Market, By Product Type: Movement Analysis
  • 5.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Product Type, 2018 - 2030
    • 5.3.1. Gene Therapy
      • 5.3.1.1. Gene Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.1.2. Ex-vivo
      • 5.3.1.2.1. Ex-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.1.3. In-vivo
      • 5.3.1.3.1. In-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Gene-Modified Cell Therapy
      • 5.3.2.1. Gene-Modified Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.2. CAR T-cell therapies
      • 5.3.2.2.1. CAR T-cell therapies Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.3. CAR-NK cell therapy
      • 5.3.2.3.1. CAR-NK cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.4. TCR-T cell therapy
      • 5.3.2.4.1. TCR-T cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.5. Others
      • 5.3.2.5.1. Others cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.3. Cell Therapy
      • 5.3.3.1. Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Cell and Gene Therapy CDMO Market, By Indication: Segment Dashboard
  • 6.2. Cell and Gene Therapy CDMO Market, By Indication: Movement Analysis
  • 6.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 6.3.1. Oncology
      • 6.3.1.1. Oncology Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.2. Infectious Diseases
      • 6.3.2.1. Infectious Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.3. Neurological Disorders
      • 6.3.3.1. Neurological Disorders Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.4. Rare Diseases
      • 6.3.4.1. Rare Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.5. Others
      • 6.3.5.1. Others Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Lonza
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Catalent, Inc
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Cytiva
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Samsung Biologics
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Thermo Fisher Scientific Inc.
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Novartis AG
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. WuXi AppTec
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. AGC Biologics
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. OmniaBio
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Rentschler Biopharma SE
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives
    • 8.2.11. Charles River Laboratories
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Financial Performance
      • 8.2.11.3. Service Benchmarking
      • 8.2.11.4. Strategic Initiatives